Similar articles

• Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine?

  Till M, MacDonell KB. Till M, et al. Ann Intern Med. 1990 Oct 1;113(7):492-4. doi: 10.7326/0003-4819-113-7-492. Ann Intern Med. 1990. PMID: 1975486 Review. No abstract available.
• Zidovudine therapy and myopathies associated with human immunodeficiency virus infection.

  Chariot P, Ruet E, Gherardi R. Chariot P, et al. Ann Neurol. 1994 Feb;35(2):247-8. doi: 10.1002/ana.410350226. Ann Neurol. 1994. PMID: 8109910 No abstract available.
• Characteristics and pathogenesis of myositis in human immunodeficiency virus infection--distinction from azidothymidine-induced myopathy.

  Espinoza LR, Aguilar JL, Espinoza CG, Gresh J, Jara J, Silveira LH, Martinez-Osuna P, Seleznick M. Espinoza LR, et al. Rheum Dis Clin North Am. 1991 Feb;17(1):117-29. Rheum Dis Clin North Am. 1991. PMID: 2041882 Review.
• HIV or zidovudine myopathy?

  Kieburtz K. Kieburtz K. Neurology. 1994 Feb;44(2):361; author reply 362-4. doi: 10.1212/wnl.44.2.361. Neurology. 1994. PMID: 8309596 No abstract available.
• [Muscular involvement in HIV infection].

  Gherardi R, Chariot P, Authier FJ. Gherardi R, et al. Rev Neurol (Paris). 1995 Nov;151(11):603-7. Rev Neurol (Paris). 1995. PMID: 8745623 Review. French.